Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Investigated for use/treatment in ovarian cancer, lung cancer, and breast cancer.
- Mechanism
- Curator reviewed
Tariquidar is an anthranilic acid derivative third generation P-glycoprotein (P-gp) inhibitors. P-gp is a transport protein found in normal cells that has many trasport and modulatory functions, from affecting the distribution and bioavailability of drugs to mediating the migration of dendritic cells. P-gp is responsible for multidrug resistance through transport of anti-cancer drugs out of their target cells. It is proposed that tariquidar's and its derivatives may bind to the H-binding site of P-gp through multiple mechanisms of binding.
- Primary indication
- Investigated for use/treatment in ovarian cancer, lung cancer, and breast cancer.Curator reviewed
- Formula / weight
- C38H38N4O6 · 646.744 g/mol (avg)
- Code names
- XR-9576
Resolves to
LGGHDPFKSSRQNS-UHFFFAOYSA-NSMILESCOC1=CC2=C(CN(CCC3=CC=C(NC(=O)C4=CC(OC)=C(OC)C=C4NC(=O)C4=CN=C5C=CC=CC5=C4)C=C3)CC2)C=C1OCWhat you can answer from here — as of June 15, 2026
Which drugs share a target with Tariquidar, and which of those have an active Phase 3 trial?